INDIA BUSINESS WORLD - OCTOBER 21^st - NOVEMBER 15^th - 2007

RANBAXY GETS NOD TO MARKET LISINOPRIL IN CANADA

Pharma Major Ranbaxy Laboratories has said it has received approval from Canadian regulatory authority for marketing hypertension drug Lisinopril in the North American country. Health Canada, Therapeutic Products Directorate, gave its approval for Ran - Lisinopril 5, 10 and 20 mg oral tablets, which has a market of 46 million Canadian Dollar (about Rs 189 crore). The tablets would be manufactured under the current Good Manufacturing Practice Regulations (cGMP) promulgated by the US Food and Drug Administration, the company said. Lisinopril will be manufactured in Ranbaxy's cGMP facility located in North Brunswick, New Jersey.